Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Deciphering the role of adipose tissue in cardiac health and disease: ADIPOhealth

Descrizione del progetto

Comunicazione tra tessuto adiposo e cuore nell’obesità

L’obesità rappresenta un importante fattore di rischio per le malattie cardiache, ma è ancora poco chiaro come l’accumulo di grasso influisca sulla funzione cardiovascolare. Il progetto ADIPOhealth, finanziato dal CER, studierà i meccanismi molecolari e fisiologici alla base della disfunzione del tessuto adiposo, comunemente noto come grasso corporeo, che causa danni cardiometabolici. Per farlo, si concentrerà sulle metabochine rilasciate dal tessuto adiposo, come proteine, metaboliti, microRNA e vescicole extracellulari, che possono alterare il metabolismo e la funzione cardiaca. Combinando dati multiomici, modelli cellulari e studi sui topi, il progetto si propone di identificare le molecole chiave coinvolte in questa interazione e di comprenderne il ruolo nelle malattie cardiache. L’obiettivo è indagare nuove strategie per prevenire o curare i disturbi cardiometabolici.

Obiettivo

Obesity is a major risk factor for cardiovascular diseases (CVD), primarily due to its disruption of heart metabolism and the alteration of crucial signaling pathways involved in maintaining cardiac function, including those regulating energy homeostasis, myocardial contractility, and stress response. Nevertheless, the underlying mechanisms for these effects remain poorly understood. Obesity leads to changes in the secretion, by adipose tissue (AT), of metabokines—proteins, peptides, metabolites, and extracellular vesicles (EVs)—that are critical for inter-organ communication and significantly affect heart function.
AT is a key endocrine organ involved in whole-body homeostasis, yet its impact on cardiac health is still not fully understood. We hypothesize that AT dysfunction is a key driver of heart disease through disrupted metabokine secretion. Our preliminary findings suggest that specific AT alterations profoundly affect heart metabolism and function. ADIPOhealth aims to advance our understanding of how AT controls cardiac function through the following objectives:
1. Identify novel metabokines (adipokines, metabolites, microproteins, microRNAs, and EVs) secreted by AT that contribute to the development of heart disease.
2. Discover novel metabokines that regulate cardiomyocyte metabolism using cellular models.
3. Investigate, in mouse models of AT-specific dysfunction, how cardiac function may be influenced by changes in metabokines.
4. Functionally characterize these metabokines in cell culture, mouse models, and human samples.
5. Develop therapeutic strategies targeting AT dysfunction and metabokine-induced cardiac damage.
By integrating multi-omics data from human and mouse studies, we aim to elucidate the molecular mechanisms by which AT influences heart health. Our results not only will deepen our understanding of metabolic crosstalk between organs but will also identify new therapeutic targets to combat cardiometabolic diseases (CMDs).

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-SyG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Contributo netto dell'UE
€ 3 300 500,00
Indirizzo
C MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
Spagna
Regione
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 3 300 500,00

Beneficiari (5)